MANEVeradermics, Incorporated
$130.57
$130.57
$37.0352 weeks$130.57
MANE in its own filings
Nothing in MANE's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
14
Events found in the filings · across 95 filings · the record starts in 2026
- Hard flags
- none
Hard flags
- Most recent filing
- Aug 11, 2026
Most recent filing · Form 10-Q
- Record starts
- Feb 5, 2026
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filinga quarter after the last one
- expected around Nov 10, 2026
- SEC comment-letter activity3 occurrences
- 2026-04-27
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 11, 2026Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress.Earnings release · press release
- Jul 15, 2026On July 15, 2026, the Company announced positive topline results from Study ‘207’ evaluating VDPHL01, a proprietary extended-release oral minoxidil formulation, in females with mild-to-moderate pattern hair loss.Regulation FD disclosure · Form 8-K
- May 12, 2026Veradermics Reports First Quarter 2026 Financial Results and.Earnings release · press release
- May 1, 2026On May 1, 2026, Veradermics, Incorporated (the “Company”) closed its underwritten public offering (the “Public Offering”) of 3,843,790 shares of the Company’s common stock, par value $0.00001 per share (the “Common Stock”), at a public offering price of $100.00 per share, pursuant to the Company’s registration …Material agreement entered · Form 8-K
- Apr 27, 2026On April 27, 2026, the Company announced positive topline data from the Phase 2/3 clinical trial, Study ‘302’ evaluating VDPHL01 in males with mild-to-moderate pattern hair loss.Regulation FD disclosure · Form 8-K
- Mar 30, 2026Veradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical Updates.Earnings release · press release
- Feb 5, 2026On February 5, 2026, in connection with the consummation of the initial public offering (the “IPO”) of shares of common stock, par value $0.00001 per share (“Common Stock”), of Veradermics, Incorporated (the “Company”), the Company filed a fifth restated certificate of incorporation (the “Restated Certificate”) with …Charter/bylaw amendment or fiscal-year change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
On our screens:Most shorted stocks
Biotechnology
The closest names by size in the same industry